Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Michelle A. Rudek; McDonald Horne; William D. Figg; William Dahut; Valerie Dyer; James M. Pluda; Eddie Reed

doi:10.1002/ajh.1076

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Michelle A. Rudek, McDonald Horne, William D. Figg^*, William Dahut, Valerie Dyer, James M. Pluda, Eddie Reed

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.

Original language	English
Pages (from-to)	51-53
Number of pages	3
Journal	American Journal of Hematology
Volume	67
Issue number	1
DOIs	https://doi.org/10.1002/ajh.1076
State	Published - 2001
Externally published	Yes

Keywords

Anemia
COL-3
Cancer
Phase I
Sideroblast
Tetracycline

Access to Document

10.1002/ajh.1076

Cite this

@article{f2069eae7350416ca2c4ee8aacc1fd9b,

title = "Reversible sideroblastic anemia associated with the tetracycline analogue COL-3",

abstract = "Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.",

keywords = "Anemia, COL-3, Cancer, Phase I, Sideroblast, Tetracycline",

author = "Rudek, {Michelle A.} and McDonald Horne and Figg, {William D.} and William Dahut and Valerie Dyer and Pluda, {James M.} and Eddie Reed",

year = "2001",

doi = "10.1002/ajh.1076",

language = "English",

volume = "67",

pages = "51--53",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc",

number = "1",

}

TY - JOUR

T1 - Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

AU - Rudek, Michelle A.

AU - Horne, McDonald

AU - Figg, William D.

AU - Dahut, William

AU - Dyer, Valerie

AU - Pluda, James M.

AU - Reed, Eddie

PY - 2001

Y1 - 2001

N2 - Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.

AB - Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.

KW - Anemia

KW - COL-3

KW - Cancer

KW - Phase I

KW - Sideroblast

KW - Tetracycline

UR - http://www.scopus.com/inward/record.url?scp=0035056156&partnerID=8YFLogxK

U2 - 10.1002/ajh.1076

DO - 10.1002/ajh.1076

M3 - Article

C2 - 11279658

AN - SCOPUS:0035056156

SN - 0361-8609

VL - 67

SP - 51

EP - 53

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Abstract

Keywords

Access to Document

Fingerprint

Cite this